Table 3.
AML1/ETO mRNA in FACS-purified cells in leukemic phase
| Case | No. of AML1/ETO+ samples/no. of samples tested
|
|||
|---|---|---|---|---|
| CD34+CD38−/lo (500 cells) | CD34+CD38+ (500 cells) | B cells (500 cells) | T cells (5,000 cells) | |
| 1 | 11/11 | 5/5 | 4/14 | 0/10 |
| 3 | 64/64 | 5/5 | 2/2 | ND |
| 4 | 10/10 | 5/5 | 3/15 | 0/9 |
| 5a | 4/4 | 5/5 | 5/75 | 0/20 |
| 6a | 30/30 | 5/5 | 5/40 | 0/21 |
| Total | 119/119 (100) | 25/25 (100) | 19/146 (13) | 0/60 (0) |
Pooled 500 CD34+ (Thy-1−)CD38−/lo cells, CD34+(Thy-1−) CD38+ cells and B cells or 5,000 T cells were analyzed by RT-PCR for AML1/ETO mRNA. Representative data are shown in Fig. 2B.